Total investments

47

Average round size

38M

Portfolio companies

34

Rounds per year

4.27

Lead investments

3

Follow on index

0.28

Exits

7

Areas of investment
BiotechnologyHealth CareHealth DiagnosticsGeneticsMedical DeviceMedicalLife SciencePharmaceuticalTherapeuticsBiopharma

Investments analytics

Analytics

Total investments
47
Lead investments
3
Exits
7
Rounds per year
4.27
Follow on index
0.28
Investments by industry
  • Biotechnology (45)
  • Health Care (27)
  • Therapeutics (25)
  • Pharmaceutical (14)
  • Medical (12)
  • Show 13 more
Investments by region
  • United States (38)
  • United Kingdom (2)
  • Italy (1)
  • Germany (1)
  • Netherlands (1)
  • Show 2 more
Peak activity year
2020

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
7
Avg. valuation at time of investment
31M
Group Appearance index
0.96
Avg. company exit year
4
Avg. multiplicator
6.15
Strategy success index
0.60

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
DISCO Pharmaceuticals 16 Jan 2024 Manufacturing, Pharmaceutical, Therapeutics Seed 23M Nordrhein-Westfalen, Cologne, Germany
Enthera 28 Jul 2020 Biotechnology, Health Care, Life Science, Pharmaceutical Early Stage Venture 33M Lombardy, Milan, Italy
JParking 01 Mar 2016 Automotive, Parking Seed 463K Guangdong, Futian, China
How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.